David J. Lockhart
Director Ejecutivo en Transcriptx, Inc. .
Cargos activos de David J. Lockhart
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Director/Miembro de la Junta | - | - |
| Director Técnico/Científico/I+D | 11/01/2022 | - | |
| Presidente | - | - | |
| Director Ejecutivo | - | 11/01/2022 | |
Transcriptx, Inc.
 Transcriptx, Inc. BiotechnologyHealth Technology Part of ReCode Therapeutics, Inc., Transcriptx, Inc. develops mRNA therapies intended to treat primary ciliary dyskinesia. The company is based in Menlo Park, CA. David J. Lockhart has been the CEO of the company since 2014. Transcriptx was acquired by ReCode Therapeutics, Inc. on March 26, 2020. | Director Ejecutivo | 01/12/2014 | - |
Historial de carrera de David J. Lockhart
Antiguos cargos conocidos de David J. Lockhart.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| AMICUS THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2006 | 31/12/2013 |
| AMBIT BIOSCIENCES CORP | Director Técnico/Científico/I+D | 01/07/2005 | 01/07/2005 |
| Fundador | 01/07/2005 | 01/07/2005 | |
| Presidente | - | 01/07/2005 | |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/02/1999 | 01/07/2000 |
| AFFYMETRIX, INC. | Corporate Officer/Principal | - | - |
Formación de David J. Lockhart.
| Stanford University | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 8 |
Operativa
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| President | 2 |
Sectorial
| Health Technology | 6 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 5 |
|---|---|
Affymetrix, Inc.
 Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Health Technology |
Transcriptx, Inc.
Transcriptx, Inc. BiotechnologyHealth Technology Part of ReCode Therapeutics, Inc., Transcriptx, Inc. develops mRNA therapies intended to treat primary ciliary dyskinesia. The company is based in Menlo Park, CA. David J. Lockhart has been the CEO of the company since 2014. Transcriptx was acquired by ReCode Therapeutics, Inc. on March 26, 2020. | Health Technology |
- Bolsa de valores
- Insiders
- David J. Lockhart
- Experiencia
